Liver Health's impact on weight loss drug tested
NCT ID NCT07428525
Summary
This study examined how a single dose of the weight loss drug AMG 133 is processed in people with different levels of liver impairment compared to those with normal liver function. It involved 36 adults to measure drug levels in the blood and check for safety issues. The goal was to understand if liver problems change how the drug works in the body.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATIC IMPAIRMENT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Clinical Pharmacology Of Miami, LLC
Miami, Florida, 33172, United States
-
Orlando Clinical Research Center
Orlando, Florida, 32809, United States
-
Panax Clinical Research
Miami Lakes, Florida, 33014-2811, United States
-
Pinnacle Clinical Research San Antonio
San Antonio, Texas, 78229-4801, United States
-
The Texas Liver Institute, Inc.
San Antonio, Texas, 78215-2100, United States
Conditions
Explore the condition pages connected to this study.